Cancer antigens targeted by drug conjugates are restricted to the few membrane receptors (such as HER2 and TROP2) that ...

Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for roughly 85 ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new two-step method promises to revolutionize targeted cancer drug development by ...

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target ...

Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the protein DLL3, demonstrated both safety and capacity to induce anticancer ...

HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with ...

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...

Phase 3 trial data support tambotatug pelitecan as a new second-line treatment for patients with relapsed small-cell lung cancer – a group with few existing treatment options.

The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard ...

Antibody-drug conjugates (ADCs) are typically composed of a monoclonal antibody attached to a cytotoxic drug via a chemical linker. The antibody is able to identify biomarkers on and attach to cancer ...